Edition:
India

I'rom Group Co Ltd (2372.T)

2372.T on Tokyo Stock Exchange

2,033JPY
6:55am IST
Change (% chg)

¥22 (+1.09%)
Prev Close
¥2,011
Open
¥2,011
Day's High
¥2,078
Day's Low
¥2,006
Volume
73,800
Avg. Vol
380,448
52-wk High
¥3,545
52-wk Low
¥1,420

Latest Key Developments (Source: Significant Developments)

I'rom Group signs cooperation agreement with DENDRIX on advanced medical business
Monday, 28 May 2018 

May 28 (Reuters) - I'rom Group Co Ltd <2372.T>:Says it signs cooperation agreement with DENDRIX Inc. on advanced medical business .Says they will mainly cooperate on cell processing center related contract manufacturing and cell processing technology development .  Full Article

I'rom Group unit signs iPS cell tech related license agreement with Q-State Biosciences
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - I'rom Group Co Ltd <2372.T>:Says co's wholly owned unit ID Pharma signs iPS cell (induced pluripotent stem cell) technology related license agreement with U.S.-based firm Q-State Biosciences Inc.  Full Article

I'rom Group says business and capital alliance with OKWAVE unit
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - I'rom Group Co Ltd <2372.T>:Says co signs business and capital alliance agreement with OKWAVE <<<3808.NG>>> unit OKEIOS, which is mainly engaged in medical information handling systems related design, development and sales .Says co plans to acquire shares of OKEIOS.  Full Article

I'rom Group unit announces success in production process of retinal pigment degeneration treatment
Wednesday, 20 Jul 2016 

I'rom Group Co Ltd <2372.T>:Says its wholly owned unit announced success in production process of retinal pigment degeneration treatment, under cooperation with Kyushu University.  Full Article

I'rom Group unit ID Pharma to grant technology license to KOHJIN BIO
Tuesday, 12 Jul 2016 

I'rom Group Co Ltd <2372.T>:Says unit ID Pharma to grant non-exclusive rights in Japan regarding technology license for cancer treatment by amplifing dendritic cells, to Japan-based co KOHJIN BIO.  Full Article

BRIEF- I'rom Group unit ID Pharma signs iPS cell generation technology licensing agreement with U.S.-based QurAlis

* Says its wholly owned unit ID Pharma concluded an iPS cell generation technology licensing agreement with U.S.-based QurAlis Corporation